These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38994196)

  • 1. Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li X; Xu J
    Front Pharmacol; 2024; 15():1392239. PubMed ID: 38994196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
    Gu Y; Zhuang Q
    Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
    [No Abstract]   [Full Text] [Related]  

  • 3. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
    Sun Z; Na X; Chu S
    Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
    Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
    Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
    Yang Y; Liu Y; Mao Z; Mao J; Jin Y
    Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model.
    Liu Q; Huang Z; Mao Z
    Front Public Health; 2023; 11():1265756. PubMed ID: 38106910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.
    Wang J; Zhang S; Wang C; Li J; Wang R; Zhu L
    BMC Health Serv Res; 2024 Jun; 24(1):771. PubMed ID: 38951849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An empirical study of the impact of generic drug competition on drug market prices in China.
    Yina C; Pengcheng L; Haomiao N; Yang C
    Front Public Health; 2023; 11():1146531. PubMed ID: 37304112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving access to medicines and beyond: the national volume-based procurement policy in China.
    Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on the impact of R&D input intensity on technological innovation output - Based on data from China's high technology industry.
    Jin C; Li D
    PLoS One; 2023; 18(10):e0292851. PubMed ID: 37847711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design.
    Hua YF; Lu J; Bai B; Zhao HQ
    Front Public Health; 2021; 9():809453. PubMed ID: 35178375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
    Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
    BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Technological Innovation Affect China's Pharmaceutical Smart Manufacturing Industrial Upgrading.
    Wang S; Chen Y
    J Healthc Eng; 2021; 2021():3342153. PubMed ID: 34868514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incentive effect of tax preferences towards the technological innovation of enterprises--Based on China's GEM listed companies.
    Ding L; Wu Y; Long J
    PLoS One; 2023; 18(4):e0282692. PubMed ID: 37058543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
    Long H; Yang Y; Geng X; Mao Z; Mao Z
    Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.